Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TECH vs BIIB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BIIB Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–6 Matrix Metrics)

BIIB Overall Winner 6-Pillar Tally: TECH 1 – 5 BIIB Matrix Metrics: TECH 6 – 4 BIIB

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Bio-Techne Corp. (TECH) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TECH carries a Unified Composite Score of 52.4/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin).

  • Composite vs. Pillar Nuance: While TECH currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 21.7% operating margin) and revenue trajectory (+10.6% vs. +4.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TECH vs BIIB
TECH NASDAQ
Bio-Techne Corp.
Biological Products, (No Disgnostic Substances)
$72.79
-0.01% 1D
Market Cap $11.4B
TTM Revenue $1.23B
Forward P/E 42.8x
Beta / 30D Vol 0.37β · 1% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 61
RSI-14: 60.7 · SMA20: $72.71 · SMA50: $72.54
BIIB NASDAQ Head-to-Head Winner
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
TTM Revenue $10.3B
Forward P/E 15.6x
Beta / 30D Vol 0.27β · 36% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 60.3 · SMA20: $250.29 · SMA50: $234.03

6-Pillar Scorecard Institutional Category Breakdown (TECH 1 – 5 BIIB)

Columns: Metric · TECH · BIIB
1. Valuation Multiples BIIB
Forward P/E 42.8x 15.6x
Trailing P/E 66.8x 109.9x
PEG Ratio 2.18x 3.45x
EV / Revenue 9.3x 4.2x
2. Growth & Scale BIIB
Revenue Growth (YoY) +4.6% +10.6%
Earnings Growth (YoY) -25.0% -84.8%
TTM Revenue (USD) $1.23B $10.3B
Market Cap $11.4B $37.0B
3. Profitability & Quality BIIB
Gross Margin 66.2% 75.8%
Operating Margin 21.7% 23.5%
Net Profit Margin 14.0% 3.4%
Return on Equity (ROE) 8.3% 1.9%
4. Balance Sheet & Cash Flow TECH
Cash Generation (TTM) $325M EBITDA $1.64B
Cash Flow Margin 26.5% EBITDA Mgn 16.0%
Net Cash / Leverage $13.79 Book/Sh · 8.3% ROE $6.50B Net Debt (0.41x D/E)
Dividend Yield 0.33% None (0.00%)
5. Options & Positioning BIIB
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 40.9% (6th %ile) 18.4% (6th %ile)
Put/Call OI Skew N/A 0.77x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat BIIB
OpEx & R&D Intensity 44.5% of Rev ($547M) 52.3% of Rev ($5.39B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TECH (6) vs BIIB (4)
Institutional Metric TECH BIIB Criterion Row Edge
Market Capitalization
Scale
$11.4B $37.0B Larger Scale BIIB
Trailing P/E Ratio
Valuation
66.8x 109.9x Lower Multiple TECH
Forward P/E Ratio
Valuation
42.8x 15.6x Lower Multiple BIIB
Revenue Growth (YoY)
Growth
+4.6% +10.6% Higher Growth BIIB
Operating Margin (TTM)
Profitability
21.7% 23.5% Higher Margin BIIB
Net Profit Margin
Profitability
14.0% 3.4% Higher Margin TECH
Return on Equity (ROE)
Capital Efficiency
8.3% 1.9% Higher ROE TECH
52-Week Range Position
Momentum
100% ($43–$73) 92% ($160–$261) Stronger Trend TECH
Beta / 30D Volatility
Risk Regime
0.37β · 1% Vol 0.27β · 36% Vol Lower Realized Risk TECH
Unified Institutional Score
Composite Signal
52.4 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite TECH
Trailing 12M Revenue (USD)
Operating Scale
$1.23B $10.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
66.2% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.18x PEG · 9.3x EV/Rev 3.45x PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$325M EBITDA ($13.79 Book/Sh · 8.3% ROE) $1.64B ($6.50B Net Debt (0.41x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BIIB +8.33 pp
TECH: +0.3% · BIIB: +8.63%
3M Horizon BIIB +18.11 pp
TECH: +0.79% · BIIB: +18.9%
6M Horizon TECH +32.14 pp
TECH: +63.83% · BIIB: +31.69%
1Y Horizon BIIB +33.59 pp
TECH: +19.82% · BIIB: +53.41%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TECH vs BIIB. Trailing 12-month operating profitability (TECH 21.7% vs BIIB 23.5%) and valuation multiples (TECH 42.8x vs BIIB 15.6x Forward P/E) are benchmarked directly in Pillar 4 below.

TECH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.23B
Gross Margin66.2%
Op. Margin21.7%
ROE / Fwd P/E8.3% · 42.8x
BIIB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10.3B
Gross Margin75.8%
Op. Margin23.5%
ROE / Fwd P/E1.9% · 15.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TECH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 40.9%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TECH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BIIB CONSOLIDATION
17d in phase · OBV ACCUMULATION
Current IV 18.4%
IV Percentile 6th %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact BIIB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TECH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.4B market capitalization and 21.7% operating margin.
OpEx & R&D Reinvestment 44.5% of Rev ($547M)
90D Engineering Disclosures 0 Published
BIIB Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $37.0B market capitalization and 23.5% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($5.39B)
90D Engineering Disclosures 0 Published

Investor FAQ TECH vs BIIB Key Questions & Quantitative Answers

As of Nov 16, 2026, Biogen Inc. (BIIB) is the stronger overall head-to-head candidate over Bio-Techne Corp. (TECH) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TECH carries a Unified Composite Score of 52.4/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin), whereas BIIB carries 50.2/100 (HOLD) at $252.72 (15.6x Forward P/E, 23.5% operating margin). Composite vs. Pillar Nuance: While TECH currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. BIIB 50.2/100 HOLD), BIIB captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (23.5% vs. 21.7% operating margin) and revenue trajectory (+10.6% vs. +4.6% YoY).

BIIB leads the Growth & Scale pillar: TECH posts +4.6% YoY revenue growth and -25.0% YoY earnings growth on $1.23B TTM revenue (66.2% gross margin, 21.7% operating margin), compared with BIIB at +10.6% YoY revenue growth and -84.8% YoY earnings growth on $10.3B TTM revenue (75.8% gross margin, 23.5% operating margin). On trailing 12-month operating scale, TECH generates $1.23B in USD-normalized revenue versus $10.3B for BIIB. In operating R&D and SG&A reinvestment, TECH deploys 44.5% of Rev ($547M) (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($5.39B) (0 disclosures) for BIIB.

BIIB screens cheaper on headline valuation multiples. TECH trades at 42.8x Forward P/E, 66.8x Trailing P/E, 2.18x PEG, and 9.3x EV/Revenue (26.5% EBITDA margin), whereas BIIB trades at 15.6x Forward P/E, 109.9x Trailing P/E, 3.45x PEG, and 4.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TECH (8.3% ROE) versus BIIB (1.9% ROE) capital efficiency.

In options market volatility and institutional positioning, TECH carries 40.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 1% Vol realized risk). By comparison, BIIB carries 18.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.27β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.